Given Imaging Guides Ingestible Microcapsule Through De Novo Process
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging hopes to be the second company to have a product cleared by way of FDA's de novo program this year by proposing to include several cautionary statements in the labeling of its wireless endoscopy diagnostic imaging system.
You may also be interested in...
Telemetric gastrointestinal capsules
FDA guidance document for device 510(k)s includes patient labeling as one of seven special controls. Patients should be aware of issues of electromagnetic interference and limitations of physical activity, the Nov. 28 guidance states. Given Imaging's M2A capsule, which was approved through the de novo 510(k) process Aug. 1 after initially being designated Class III, can take roughly 24 hours to move through a patient's digestive tract (1"The Gray Sheet" July 30, 2001, p. 14)...
Telemetric gastrointestinal capsules
FDA guidance document for device 510(k)s includes patient labeling as one of seven special controls. Patients should be aware of issues of electromagnetic interference and limitations of physical activity, the Nov. 28 guidance states. Given Imaging's M2A capsule, which was approved through the de novo 510(k) process Aug. 1 after initially being designated Class III, can take roughly 24 hours to move through a patient's digestive tract (1"The Gray Sheet" July 30, 2001, p. 14)...
Given Imaging Goes Public, TheraSense Up Next Despite Market Uncertainties
TheraSense and Given Imaging are moving forward with planned initial public offerings despite a volatile economic environment in the wake of the Sept. 11 terrorist attacks..